GlassScriptPhysician profile
Ehab Hussein
NPI 1740449495
$24,904.23
in general payments reported to CMS, 2019-2025
26 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $194 · 2021: $11.54 · 2022: $477 · 2023: $3,526 · 2024: $18K · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,971 · Education: $6,500 · Consulting Fee: $6,250 · Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,971.21 |
| Education | $6,500.00 |
| Consulting Fee | $6,250.00 |
| Food and Beverage | $2,126.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,072.55 | 2022-2025 | |
| Inari Medical, INC. | $10,860.20 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pulmonx Corporation | $1,249.30 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Noah Medical Corporation | $534.76 | 2023-2024 | Galaxy |
| Ethicon INC. | $339.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $151.31 | 2024-2025 | Libtayo, Dupixent |
| Merck Sharp & Dohme LLC | $117.08 | 2019-2025 | Winrevair |
| Medtronic, INC. | $104.35 | 2023 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $91.52 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.39 | 2019-2025 | Nucala, Trelegy Ellipta |
| Olympus America INC. | $44.93 | 2023 | Spiration Valve System |
| Harmony Biosciences LLC | $32.38 | 2023 | Wakix |
| Ani Pharmaceuticals, INC. | $30.64 | 2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $27.23 | 2025 | Lumryz |
| Bard Access Systems, INC. | $25.72 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $19.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2020 | |
| Covis Pharma Gmbh | $18.73 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.94 | 2020 | |
| Gilead Sciences, INC. | $17.43 | 2023 | |
| Mylan Specialty L.P. | $16.58 | 2022 | |
| Advanced Respiratory, INC | $16.23 | 2019 | |
| Insmed, INC. | $12.91 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.12 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.04 | 2020 | |
| Grifols USA, LLC | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.